Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rabeprazole
- Development stage
- Approved
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Rabeprazole is a small molecule pharmaceutical drug in the class of proton pump inhibitors (PPIs). It is primarily used to treat conditions involving excessive stomach acid production, such as gastroesophageal reflux disease (GERD), peptic ulcer disease, and Zollinger-Ellison syndrome. Rabeprazole is also used in combination with antibiotics to eradicate Helicobacter pylori infection associated with duodenal ulcers. The drug acts by irreversibly inhibiting the gastric H+, K+-ATPase enzyme (the "proton pump") located on the secretory surface of gastric parietal cells. This inhibition blocks the final step of gastric acid secretion, leading to reduced acidity in the stomach and allowing healing of acid-related damage[1][2][4][5][6]. Rabeprazole is a prodrug that becomes activated in acidic environments within parietal cells and forms covalent bonds with cysteine residues on the proton pump[5]. It has a relatively rapid onset compared to other PPIs due to its higher pKa value[8].
- Brand names
- AcipHexParietAcipHex Sprinkle
- Other names
- idiazole
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on rabeprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rabeprazole.